文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

早产儿生理药代动力学模型第二部分:预测早产儿药物药代动力学的应用

Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

本研究开发并验证了一个早产儿生理药代动力学(PBPK)模型,使用阿芬太尼、咪达唑仑、咖啡因、布洛芬、庆大霉素和万古霉素六种药物,基于成人体内处置知识预测早产儿药代动力学。模型结合CYP1A2、CYP2C9、CYP3A4的个体发育函数及肾功能成熟,预测参数均在二倍误差范围内。该模型虽不替代临床研究,但可辅助首次给药剂量决策和研究设计。

要点

  • 早产儿PBPK模型能预测多种肾/肝清除药物的药代动力学,所有参数预测误差在二倍以内。
  • 模型整合CYP1A2、CYP2C9、CYP3A4个体发育函数,可预测口服和静脉给药后的PK变化。
  • 肾功能成熟函数可预测庆大霉素和万古霉素静脉给药后的暴露。

核心结论

  • 开发的早产儿PBPK模型能合理预测六种不同清除途径药物的药代动力学,所有PK参数预测均在二倍误差范围内。
  • 该模型虽不能替代临床研究,但可潜在帮助决定早产儿首次给药剂量和研究设计。

研究设计与样本

  • 在Simcyp Simulator V17中开发早产儿PBPK模型,从文献收集阿芬太尼、咪达唑仑、咖啡因、布洛芬、庆大霉素和万古霉素的药物参数。
  • 将预测的PK参数和曲线与观察数据进行比较,评估模型的可预测性。

主要发现

  • 模型使用CYP1A2、CYP2C9和CYP3A4的个体发育函数,预测了六种化合物口服和静脉给药后的PK变化。
  • 对于庆大霉素和万古霉素,肾功能成熟能预测静脉给药后的暴露。
  • 所有PK参数预测均在二倍误差标准内。

临床怎么用

  • 在缺乏临床数据时,可用该模型辅助决定早产儿首次给药剂量和研究设计。
  • 模型预测结果不应替代临床研究,但可作为剂量调整的参考。

局限性

  • 模型并非用于替代临床研究。
  • 仅验证了六种药物,未涵盖其他清除途径或药物类别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm neonates are usually not part of a traditional drug development programme, however they are frequently administered medicines. Developing modelling and simulation tools, such as physiologically based pharmacokinetic (PBPK) models that incorporate developmental physiology and maturation of drug metabolism, can be used to predict drug exposure in this group of patients, and may help to optimize drug dose adjustment. OBJECTIVE: The aim of this study was to assess and verify the predictability of a preterm PBPK model using compounds that undergo diverse renal and/or hepatic clearance based on the knowledge of their disposition in adults. METHODS: A PBPK model was developed in the Simcyp Simulator V17 to predict the pharmacokinetics (PK) of drugs in preterm neonates. Drug parameters for alfentanil, midazolam, caffeine, ibuprofen, gentamicin and vancomycin were collated from the literature. Predicted PK parameters and profiles were compared against the observed data. RESULTS: The preterm PBPK model predicted the PK changes of the six compounds using ontogeny functions for cytochrome P450 (CYP) 1A2, CYP2C9 and CYP3A4 after oral and intravenous administrations. For gentamicin and vancomycin, the maturation of renal function was able to predict the exposure of these two compounds after intravenous administration. All PK parameter predictions were within a twofold error criteria. CONCLUSION: While the developed preterm model for the prediction of PK behaviour in preterm patients is not intended to replace clinical studies, it can potentially help with deciding on first-time dosing in this population and study design in the absence of clinical data.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Abduljalil K, Pan X, Pansari A, et al. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population. Clin Pharmacokinet. 2020. PMID: 31587145. doi:10.1007/s40262-019-00827-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。